BERKELEY, Calif.--Neomorphic Software has closed a deal with SyStemix, a Novartis company. Neomorphic's hidden-Markov-model-based technology will be used to find novel genes in SyStemix's proprietary sequences that are unable to be classified using existing sequence analysis tools. Martin Reese, Neomorphic's chief scientific officer, said the deal would give Neomorphic "the opportunity to work closely with geneticists to verify and optimize this technology towards the discovery of new genes."
SyStemix Uses Neomorphic Software to Identify Genes
Jun 04, 1999